Division of Infectious Diseases, Tropical Medicine and AIDS, Department of Internal Medicine, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, The Netherlands.
Clin Microbiol Infect. 2012 Apr;18(4):E84-90. doi: 10.1111/j.1469-0691.2012.03773.x. Epub 2012 Feb 13.
A significant proportion of women develop a recurrence following an initial urinary tract infection (UTI). In women with recurrent UTI, the predictive value of asymptomatic bacteriuria (ASB) for the development of a subsequent UTI has not yet been established and it is not known whether information from an asymptomatic sample is useful in guiding antimicrobial therapy. To address these questions, we used data that originated from the 'Non-antibiotic prophylaxis for recurrent urinary tract infections' (NAPRUTI) study: two randomized controlled trials on the prevention of recurrent UTI in non-hospitalized premenopausal and postmenopausal women (n=445). During 15months of follow-up, no difference was observed in the time to a subsequent UTI between women with and without ASB at baseline (hazard ratio: 1.07, 95% CI 0.80-1.42). The antimicrobial susceptibility and pulsed-field gel-electrophoresis (PFGE) pattern of 50 Escherichia coli strains causing a UTI were compared with those of the ASB strain isolated 1month previously. The predictive values of the susceptibility pattern of the ASB strain, based on resistance prevalence at baseline, were ≥76%, except in the case of nitrofurantoin- and amoxicillin-clavulanic acid-resistance. Asymptomatic and symptomatic isolates had similar PFGE patterns in 70% (35/50) of the patients. In the present study among women with recurrent UTI receiving prophylaxis, ASB was not predictive for the development of a UTI. However, the susceptibility pattern of E. coli strains isolated in the month before a symptomatic E. coli UTI can be used to make informed choices for empirical antibiotic treatment in this patient population.
相当一部分女性在初次尿路感染 (UTI) 后会复发。在复发性 UTI 女性中,无症状菌尿 (ASB) 对随后 UTI 发展的预测价值尚未确定,也不知道无症状样本中的信息是否有助于指导抗菌治疗。为了回答这些问题,我们使用了源自“非抗生素预防复发性尿路感染”(NAPRUTI)研究的数据:两项针对非住院绝经前和绝经后女性复发性 UTI 预防的随机对照试验(n=445)。在 15 个月的随访期间,基线时有无 ASB 的女性在随后发生 UTI 的时间上没有差异(风险比:1.07,95%CI 0.80-1.42)。比较了引起 UTI 的 50 株大肠埃希菌的药敏和脉冲场凝胶电泳(PFGE)模式与 1 个月前分离的 ASB 菌株的药敏和 PFGE 模式。基于基线耐药率,ASB 菌株药敏模式的预测值≥76%,除了对呋喃妥因和阿莫西林克拉维酸的耐药率。70%(35/50)的患者无症状和有症状的分离株具有相似的 PFGE 模式。在本研究中,在接受预防治疗的复发性 UTI 女性中,ASB 对 UTI 的发生没有预测作用。然而,在有症状大肠埃希菌 UTI 前一个月分离的大肠埃希菌菌株的药敏模式可用于为该患者人群的经验性抗生素治疗做出明智选择。